Unichem Laboratories Limited (IN:UNICHEMLAB)
:UNICHEMLAB
Top Page
Unichem Laboratories Limited
(UNICHEMLAB)
Select Model
Select Model
Rating:61Neutral
Price Target:
₹317.00
▼(-28.45% Downside)
Action:ReiteratedDate:02/07/26
The score is led by solid financial fundamentals (growth and a low-leverage balance sheet) but is held back by negative 2025 operating/free cash flow and only modest profitability. Technicals are weak-to-neutral with the stock below key longer-term moving averages, while valuation is supportive due to the low P/E.
Positive Factors
Revenue Growth
Sustained revenue growth (18.18% 5-year trend) demonstrates durable demand and successful market expansion across domestic branded formulations, exports and API sales. This scale improves bargaining power, spreads fixed costs and supports reinvestment in R&D and manufacturing over the medium term.
Negative Factors
Negative Operating Cash Flow
Operating cash flow turning negative and persistent negative free cash flow signal weak cash conversion despite revenue growth. This undermines the firm's ability to self-fund capex, regulatory approvals and working capital, increasing reliance on external financing or equity issuance over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained revenue growth (18.18% 5-year trend) demonstrates durable demand and successful market expansion across domestic branded formulations, exports and API sales. This scale improves bargaining power, spreads fixed costs and supports reinvestment in R&D and manufacturing over the medium term.
Read all positive factors
Unichem Laboratories Limited (UNICHEMLAB) vs. iShares MSCI India ETF (INDA)
Market Cap
₹23.22B
Dividend YieldN/A
Average Volume (3M)1.03K
Price to Earnings (P/E)2.9
Beta (1Y)1.10
Revenue Growth25.42%
EPS GrowthN/A
CountryIN
Employees2,875
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)37.54
Shares Outstanding70,405,754
10 Day Avg. Volume1,013
30 Day Avg. Volume1,033
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)2.00
Price to Sales (P/S)2.32
P/FCF Ratio-33.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Unichem Laboratories Limited Business Overview & Revenue Model
Company Description
Unichem Laboratories Limited, a pharmaceutical company, manufactures and sells pharmaceutical products worldwide. It offers formulation products that address various therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry,...
How the Company Makes Money
Unichem Laboratories makes money primarily by selling pharmaceutical products, with revenue largely coming from (1) branded formulations sold in India through prescriptions written by physicians and dispensed via pharmacies/hospitals, supported by...
Unichem Laboratories Limited Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
72
Positive
Cash Flow
50
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 22.26B | 21.11B | 16.57B | 13.25B | 12.56B | 12.05B |
| Gross Profit | 11.23B | 12.47B | 3.17B | 7.92B | 8.07B | 7.89B |
| EBITDA | 2.50B | 2.65B | 742.36M | -456.07M | 1.18B | 1.41B |
| Net Income | 884.60M | 1.38B | -704.74M | -2.02B | 330.62M | 343.25M |
Balance Sheet | ||||||
| Total Assets | 35.56B | 35.69B | 31.69B | 31.93B | 33.19B | 31.26B |
| Cash, Cash Equivalents and Short-Term Investments | 1.94B | 895.80M | 1.52B | 1.89B | 3.73B | 3.14B |
| Total Debt | 5.02B | 4.60B | 2.48B | 3.14B | 3.49B | 1.19B |
| Total Liabilities | 11.21B | 11.19B | 8.07B | 7.58B | 7.00B | 5.69B |
| Stockholders Equity | 24.35B | 24.51B | 23.62B | 24.35B | 26.18B | 25.57B |
Cash Flow | ||||||
| Free Cash Flow | 408.30M | -1.44B | -58.53M | -1.29B | -3.87B | -2.55B |
| Operating Cash Flow | 994.40M | -70.20M | 166.94M | -850.91M | -2.60B | 330.99M |
| Investing Cash Flow | -375.90M | -2.41B | 504.04M | 2.03B | 1.00B | -735.58M |
| Financing Cash Flow | 259.10M | 1.84B | -1.06B | -813.00M | 1.91B | -1.21B |
Unichem Laboratories Limited Technical Analysis
Neutral
443.05
Price Trends
346.79
Negative
396.89
Negative
463.72
Negative
Market Momentum
-11.19
Negative
54.20
Neutral
79.41
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:UNICHEMLAB, the sentiment is Neutral. The current price of 443.05 is above the 20-day moving average (MA) of 310.38, above the 50-day MA of 346.79, and below the 200-day MA of 463.72, indicating a neutral trend. The MACD of -11.19 indicates Negative momentum. The RSI at 54.20 is Neutral, neither overbought nor oversold. The STOCH value of 79.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:UNICHEMLAB.
Unichem Laboratories Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹31.15B | 43.39 | ― | 0.85% | ― | ― | |
61 Neutral | ₹23.22B | 2.94 | ― | ― | 25.42% | ― | |
61 Neutral | ₹25.41B | -74.58 | ― | ― | 5.38% | ― | |
57 Neutral | ₹32.97B | 23.17 | ― | 0.24% | 4.08% | 31.52% | |
57 Neutral | ₹30.13B | 67.80 | ― | 0.03% | 7.78% | -34.68% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:UNICHEMLAB
Unichem Laboratories Limited
329.85
-224.90
-40.54%
IN:AARTIDRUGS
Aarti Drugs Limited
361.25
40.77
12.72%
IN:DCAL
Dishman Carbogen Amcis Ltd.
162.10
-25.40
-13.55%
IN:GUFICBIO
Gufic Biosciences Limited
300.50
-9.77
-3.15%
IN:RPGLIFE
RPG Life Sciences Limited
1,883.25
-68.78
-3.52%
Unichem Laboratories Limited Corporate Events
Unichem Shareholders Clear Director Appointment and Key Related-Party Deals via Postal Ballot
Mar 30, 2026
Unichem Laboratories has announced the results of a postal ballot in which shareholders approved all resolutions put to remote e-vote, including the appointment of Dr. Swati Patankar as a non-executive independent director for a five-year term sta...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.